Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

203 results about "Carnitine" patented technology

Carnitine (β-hydroxy-γ-N-trimethylaminobutyric acid, 3-hydroxy-4-N,N,N-trimethylaminobutyrate) is a quaternary ammonium compound involved in metabolism in most mammals, plants, and some bacteria. Carnitine may exist in two isomers, labeled D-carnitine and L-carnitine, which are both biologically active. At room temperature, pure carnitine is a white powder, and a water-soluble zwitterion with low toxicity. Carnitine only exists in animals as the L-enantiomer, and D-carnitine is toxic because it inhibits the activity of L-carnitine. Carnitine, derived from an amino acid, is found in nearly all organisms and animal tissue. Carnitine is the generic expression for a number of compounds that include L-carnitine, acetyl-L-carnitine, and propionyl-L-carnitine. It is most accumulated in cardiac and skeletal muscles as it accounts for 0.1% of its dry matter. It was first derived from meat extracts in 1905, therefore the name carnitine is derived from Latin "carnus" or flesh. The body synthesizes enough carnitine from lysine side chains to keep up with the needs of energy production in the body as carnitine acts as a transporter of long-chain fatty acids into the mitochondria to be oxidized and produce energy. Some individuals with genetic or medical disorders (such as preterm infants) cannot make enough, so this makes carnitine a conditionally essential nutrient for them.

Biomarkers and use thereof for diagnosis, prevention, and treatment of muscle atrophy

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.
Owner:MYOMAR MOLECULAR INC

Feed premix for improving chicken quality

The invention provides a feed premix for improving chicken quality. The fresh-keeping agent is prepared from the following components in percentage by weight: 5%-15% of a flavor enhancing component, 10%-25% of a tenderness improving component, 3%-10% of an antioxidant fresh-keeping component, 2%-3% of a function enhancing component and the balance of a carrier and a diluent, the function strengthening component is prepared from beta-alanine embedded citronella essential oil and konjac glucomannan zymolyte; the flavor enhancing component comprises a rosemary extract, a yeast culture and curcumin in a mass ratio of (2-4): (1-3): 1; the tenderness improving component comprises conjugated linoleic acid, L-carnitine modified by glutamine transaminase and betaine in a mass ratio of (3-5): (2-4): 1; the antioxidant fresh-keeping component is vitamin E and tea polyphenol in a mass ratio of (1-2): 1. Through multi-component synergism and functional targeting optimization, a three-dimensional quality improvement system with enhanced flavor, improved tenderness, oxidation resistance and fresh keeping is constructed, so that the chicken quality is comprehensively upgraded.
Owner:BAIHE (SHANGHAI) BIOTECHNOLOGY CO LTD

A meal replacement powder for weight loss in obese patients and a method for preparing the same

The application belongs to the technical field of functional food, and particularly discloses a meal replacement powder for weight loss of obese patients and a preparation method thereof. The meal replacement powder comprises whey protein powder, composite dietary fiber (containing at least two kinds of konjac powder and the like), functional carbohydrate, functional fat (containing medium-chain fatty acid and the like), and composite vitamins, minerals, functional additives (L-carnitine and the like), and stability additives. The preparation comprises raw material pretreatment, small material premixing, large material mixing, microencapsulation of fat-soluble components, total mixing, sterilization and packaging, and the key lies in that the fat-soluble components are wrapped by wall materials and spray dried into microcapsules. The meal replacement powder can balance nutrition, strengthen satiety, promote fat metabolism, avoid muscle loss and electrolyte imbalance, has a shelf life of 12 months at room temperature, has good palatability, has good weight loss effect (average weight loss of 5.8 kg in 2 months), has no adverse reactions, and is suitable for long-term weight loss diet management of obese patients.
Owner:石霞

Anti-aging capsule compounded by PQQ and mitochondrial nutrients

The invention relates to an anti-aging capsule compounded by PQQ and mitochondrial nutrients, and discloses an anti-aging capsule which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion and supplementing high-purity raw materials and slow-release dosage forms to realize energy metabolism activation and anti-oxidation synergistic intervention. Therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The capsule is characterized by comprising the following components in parts by weight: 1-20 mg of pyrroloquinoline quinone disodium salt (PQQ), 20-100 mg of coenzyme Q10, 50-200 mg of L-carnitine tartrate, 10-100 mg of alpha-lipoic acid, 50-300 mg of nicotinamide mononucleotide (NMN) or nicotinamide nucleoside (NR), and 10-50 [mu] g of selenoprotein or organic selenium yeast, and a capsule carrier comprises 100 mg of gelatin or a plant-derived capsule shell, 180 mg of microcrystalline cellulose, 5 mg of magnesium stearate and 5 mg of silicon dioxide.
Owner:JIANGSU SHAREJOY HEALTH TECH CO LTD

Astragaloside synergistic composition as well as preparation method and application thereof

The invention discloses an astragaloside synergistic type composition as well as a preparation method and application of the astragaloside synergistic type composition. Comprising the following components: 8 to 16 parts of astragaloside, 20 to 40 parts of a honeysuckle flower extract, 10 to 20 parts of L-carnitine, 0.1 to 0.5 part of selenium yeast, 3 to 8 parts of diammonium glycyrrhizinate, 5 to 15 parts of taurine, 8 to 20 parts of a fructus forsythiae extract, 2 to 7 parts of vitamin E, 12 to 32 parts of hydroxypropyl-beta-cyclodextrin, 2 to 10.5 parts of maltodextrin, 1 to 7 parts of Arabic gum, 10 to 20 parts of lactose, 1 to 3 parts of zinc gluconate and 2 to 5 parts of magnesium stearate. 1-3 parts of vitamin C, 1-5 parts of xanthan gum and 1-3 parts of lecithin. The composition has a wide application prospect in preparation of veterinary drugs or veterinary food additives.
Owner:JIANGXI CHENGBIXIN BIOTECHNOLOGY CO LTD

Dried blood spot liquid chromatography-mass spectrometry detection method adaptive to 7 types of metabolites

The invention belongs to the technical field of biological medicine, and discloses a dry blood spot liquid chromatography-mass spectrometry detection method adaptive to 7 metabolites. According to the method, a pH / polarity double-trigger microcapsule solvent carrier system is adopted, high-polarity extraction solvents, medium-polarity extraction solvents and low-polarity extraction solvents are packaged in the pH / polarity double-trigger microcapsule solvent carrier system in a layered mode, the solvents are released in sequence according to local pH and polarity changes in the extraction process, and amino acid, acyl carnitine, organic acid, bile acid, steroid, fatty acid and glycometabolism intermediate products are efficiently extracted respectively. The method disclosed by the invention breaks through the inherent limitation of a traditional static solvent system, solves the problem of unbalanced recovery rate caused by insufficient solvent suitability in dry blood spot extraction of seven metabolites with great polarity span, and remarkably improves the accuracy, reproducibility and coverage range of a DBS-LC-MS / MS platform in synchronous detection of multi-component metabolites; and reliable technical support is provided for newborn inherited metabolic disease screening, endocrine disease diagnosis and drug metabolism research.
Owner:SHANGHAI BIOTREE

Feline triple vaccine immunoadjuvant containing two feline interleukins and a metabolic regulator molecule, compositions and uses

The present application relates to the technical field of biological medicine, and in particular to a cat triple vaccine immune adjuvant containing two kinds of cat interleukins and metabolic regulatory molecules, a composition and application. The composition comprises cat interleukin 15, cat interleukin 23 and a metabolic regulatory molecule, the metabolic regulatory molecule comprises beta-nicotinamide mononucleotide, beta-nicotinamide adenine dinucleotide disodium salt, N-acetyl cysteine and L-carnitine, and can be used for preparing a cat triple vaccine or an auxiliary preparation of the cat triple vaccine. The composition can effectively improve the protection of the vaccine, prolong the protection time of the vaccine and reduce adverse reactions; the vaccine can more durably and at a higher level reduce or control the reproductive infection of viruses, significantly improve the specific humoral immune level and memory response ability of animals, and better resist the invasion and spread of FPV, FCV and FHV-1.
Owner:SICHUAN SANYOUKANG BIOTECHNOLOGY CO LTD

Complete-cycle nutrition-enhanced goat hybridization breeding method

The invention relates to the technical field of livestock and poultry breeding, in particular to a goat hybridization breeding method capable of achieving complete-cycle nutrition enhancement. The core of the method is that systematic nutrition intervention runs through the whole breeding process. Before hybridization, performing differential nutrition pretreatment on the parents for 60 days: feeding the female parents with a breeding nutrition enhancer added with components such as D-chiro-inositol and N-acetylcysteine, and supplementing sperm motility enhancer containing acetylated L-carnitine and ergothioneine to the male parents. In the gamete treatment stage, the oocytes are subjected to in-vitro maturation culture in a special culture solution containing components such as D-chiro-inositol and a growth differentiation factor 9; after the sperms are subjected to gradient centrifugal screening, completing in-vitro fertilization in an optimized fertilization culture solution; after the embryos develop into blastocysts in the sequential culture system, carrying out laparoscopic transplantation, and carrying out staged precise nutrition culture on the pregnant ewes. According to the method, through multi-level nutrition enhancement, the reproductive capacity of the goats and the growth performance of offspring are effectively improved.
Owner:XINJIANG ACAD OF ANIMAL SCI

Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

PendingUS20260137646A1Nervous disorderImmunological disordersCompulsive disordersNervous system
Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.
Owner:EPITRACKER INC

Composition for assisting in improving eosinophilic esophagitis and application thereof

The invention relates to the technical field of compositions, and particularly discloses a composition for assisting in improving eosinophilic esophagitis and application of the composition. The composition for assisting in improving eosinophilic esophagitis provided by the invention comprises an iron source, a zinc source and L-carnitine. By optimizing the components of the composition and specifically limiting the proportion of the iron source, the zinc source and the L-carnitine in the composition, esophageal epithelial hyperplasia can be effectively reversed, the number of bifidobacteria is increased, the number of enterobacter and esophageal tissue eosinophilic granulocytes is reduced, the level of IL-13 cell factors is reduced, and the curative effect is improved. Further, the effect of remarkably assisting in improving eosinophilic granulocytic esophagitis is achieved.
Owner:JUNLEBAO DAIRY GRP CO LTD

Use of carnitine palmitoyltransferase 1 inhibitors in the treatment of heart failure with preserved ejection fraction

The present invention relates to the use of carnitine palmitoyltransferase 1 inhibitors in the treatment of heart failure with preserved ejection fraction. The use in particular is the use of the carnitine palmitoyltransferase (CPT1) inhibitor Etomoxir for the prevention and / or treatment of heart failure with preserved ejection fraction by oral administration.
Owner:BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES

A direct qPCR amplification reagent, amplification kit and application for whole blood samples

This invention discloses direct amplification qPCR reagents, kits, and applications for whole blood samples. The amplification reagents include: a composite hot-start DNA polymerase system, a buffer system, a surfactant, an anti-contamination system, and an anti-inhibition enhancer system. The composite hot-start DNA polymerase system is obtained by mixing antibody-modified hot-start Taq enzyme and antibody-modified Taq1C2 mutant Taq enzyme in a predetermined ratio. The buffer system includes Tris-HCl, MgCl2, (NH4)2SO4, and KCl. The surfactants include Tween-20 and NP-40. The anti-contamination system includes UDG enzyme and dNTPs, wherein the dNTPs are composed of dATP, dGTP, dCTP, dTTP, and dUTP. The anti-inhibition enhancer system includes D-trehalose, L-carnitine, DMSO, BSA, and SSB single-chain binding protein.
Owner:河南远止生物技术有限公司 +2

Cell culture medium supplement as well as preparation method and application thereof

The invention discloses a cell culture medium supplement as well as a preparation method and application thereof, and relates to the technical field of cell biology. The supplement comprises DL-alpha-tocopheryl acetate, linolenic acid, ethanolamine, L-carnitine hydrochloride, 3, 3 ', 5-triiodoL-sodium thyrosinate, and serum albumin. As a cell culture additive with definite chemical components and simple composition, the cell culture additive can replace a traditional culture system with unknown chemical components or too complex composition, and is used for supporting proliferation, differentiation and characterization analysis of cells. The culture medium additive is clear in chemical component, simple to prepare, stable in effect and relatively low in cost, can promote in-vitro proliferation and oxidation resistance of cells including human embryonic stem cells and mesenchymal stem cells, and has important application value in actual production.
Owner:UNIV OF MACAU

Metabolite marker for colorectal cancer diagnosis and application thereof

The invention relates to a metabolite marker for early diagnosis of colorectal cancer as well as application and a device of the metabolite marker. The marker comprises sulfate, ubiquinone-1, a deoxycholic acid glycine conjugate, demethylchlorophyllin, 3-(3, 5-diiodine-4-hydroxyphenyl) lactate, vitamin K1, O-decanoyl-L-carnitine, sedoheptulose 1, 7-diphosphoric acid, cholesterol-docosahexaenoic acid ester and acyl AMP (adenosine monophosphate). The marker combination has excellent performance in colorectal cancer detection, AUROC can reach 0.97, and noninvasive screening and early diagnosis of colorectal cancer can be accurately, quickly and simply realized.
Owner:MACAU UNIV OF SCI & TECH

Preparation for improving male erectile function and sperm quality and preparation process

The invention discloses a preparation for improving male erectile function and sperm quality. The health-care food is characterized by being prepared from the following raw materials in parts by weight: 30-50 parts of herba epimedii extract, 20-40 parts of herba cistanche extract, 15-30 parts of fructus lycii extract, 18-35 parts of semen cuscutae extract, 10-25 parts of herba cynomorii extract, 8-20 parts of maca powder, 6-18 parts of raspberry extract, 0.5-2 parts of lycopene, 1-3 parts of L-carnitine and 0.3-1 part of vitamin B family (vitamin B1, vitamin B2, vitamin B6 and vitamin B12 are mixed according to the mass ratio of 1: 1: 2: 0.5). The herba epimedii extract is selected as a main component, the content of icariin is regulated to be not lower than 60%, the high-content icariin can more effectively promote sex hormone secretion, enhance sexual desire and improve erectile function, the total content of echinacoside and verbascoside in the herba cistanche extract is not lower than 45%, and the herba epimedii extract and the herba cistanche extract have the effect of promoting sex hormone secretion, enhancing sexual desire and improving erectile function. The two components have the effects of tonifying kidney yang and benefiting essence and blood, and can enhance kidney functions.
Owner:TIANJIN ZHENBIAN BIANSE ENTERPRISE MANAGEMENT CO LTD

Application of marker in preparation of kit for diagnosing chronic obstructive pulmonary disease

The invention discloses application of a marker to preparation of a kit for diagnosing chronic obstructive pulmonary diseases. According to the application disclosed by the invention, the accuracy of diagnosing the chronic obstructive pulmonary disease by using (R)-3-hydroxytetradecanoic acid alone or in combination with the azelayl platelet activating factor is relatively high; on the basis of combination of (R)-3-hydroxytetradecanoic acid and an azelayl platelet activating factor, the compound is prepared. The compound can be further combined with one or two of 1-hexadecyl-2-(5-oxovaleryl)-sn-glycerol-3-phosphorylcholine, 1-O-hexadecyl-SN-glycerol-3-choline phosphoric acid, lauroyl-L-carnitine and beta-acetyl-gamma-O-alkyl-L-alpha-phosphatidylcholine to be used for diagnosing the chronic obstructive pulmonary disease. Therefore, a diagnostic kit for diagnosing the chronic obstructive pulmonary disease can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.
Owner:HENAN UNIV OF CHINESE MEDICINE

Metabolic markers for distinguishing hypertrophic cardiomyopathy from left ventricular hypertrophy and uses thereof

ActiveCN120064663BHypertrophic cardiomyopathyAdenosine diphosphate
The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for distinguishing hypertrophic cardiomyopathy and left ventricular hypertrophy and application. The application analyzes the metabolome of hypertrophic cardiomyopathy (HCM) patients, left ventricular hypertrophy (LVH) patients caused by non-hypertrophic cardiomyopathy and healthy people, finds that carnitine C16:2, carnitine C14:0, carnitine C16:0, carnitine C18:0 and carnitine C18:1 are differentially expressed in HCM patients and LVH patients, pyridoxine phosphate, ito acid, adenosine monophosphate, adenosine diphosphate and adenosine triphosphate are differentially expressed in HCM patients and healthy people, lysine base, methyl glutamic acid, acetyl proline, malate semialdehyde and citramalate are differentially expressed in LVH patients and healthy people, and ROC curve analysis shows excellent prediction effect, strong specificity and high sensitivity.
Owner:FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Functional solid beverage capable of reducing fat, losing weight and conditioning five highs and preparation method of functional solid beverage

The invention discloses a functional solid beverage capable of reducing fat, losing weight and conditioning five highs. According to the functional solid beverage, dietary fibers such as fructo-oligosaccharide, inulin and the like are used for regulating intestinal flora, a white kidney bean extract is used for inhibiting the activity of alpha-amylase, L-carnitine is used for promoting fat transport, and medicinal and edible components such as ginseng, lotus leaves and the like are matched to realize multi-way metabolism regulation. The weight percentage of each component can be adjusted within a specified range so as to adapt to different physique requirements. Animal experiments prove that the total cholesterol (TC) of serum can be obviously reduced by 21.3-25.8% and the triglyceride (TG) can be obviously reduced by 28.9-34.2% after the traditional Chinese medicine is continuously taken for 4 weeks, and meanwhile, the insulin resistance index (HOMA-IR) can be improved to 16.5-20.3%.
Owner:GUANGZHOU SHANGMEI FUYUAN LIFE TECH GRP CO LTD

Packaging box (Notrand L-carnitine electrolyte flavored beverage)

1. The name of the design product: packaging box (Norland L-carnitine electrolyte flavored beverage). 2. The use of the design product: for packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: design 1 front view. 5. Design 1 is designated as the basic design.
Owner:SHANDONG SIBOTE BIOTECHNOLOGY CO LTD

Cream with efficient mild whitening effect and preparation method thereof

The invention provides efficient mild whitening cream and a preparation method thereof. The raw materials of the cream comprise five phases A and E, the phase C contains 0.1-3% of a mixed solution of isosorbide dimethyl ether and hydroxyl pinacolone retinoate, and the phase D contains 0.01-0.1% of L-carnitine. Wherein the hydroxyl pinacolone retinoate can be specifically combined with an RAR / RXR (Region Receptor / Receptor X Receptor), and the expression of an MITF (Microphthalmia-associated Transcription Factor) gene is reduced, so that the melanogenesis is inhibited; l-carnitine promotes fatty acid beta-oxidation and enhances ATP synthesis to indirectly regulate and control AMPK activity; aMPK enhances transcriptional activity of a tretinoin receptor through phosphorylation of the tretinoin receptor, so that the AMPK and hydroxyl pinacolone retinoate exert a synergistic effect, jointly enhance whitening activity, effectively improve the phenomena of color spots and dark skin and promote the skin color to be uniform, bright and white; meanwhile, the isosorbide dimethyl ether can promote the transdermal absorption of the hydroxyl pinacolone retinoate, the L-carnitine and the related active ingredients.
Owner:SHANGHAI CHUANGMEIYAN COSMETICS TECH CO LTD

Application of reagent for detecting plasma metabolism marker combination in preparation of product for diagnosing breast cancer

The invention discloses application of a reagent for detecting a plasma metabolism marker combination in preparation of a product for diagnosing breast cancer, and belongs to the field of breast cancer markers. According to the application of the reagent for detecting the plasma metabolism marker combination in preparing the product for diagnosing the breast cancer, the plasma metabolism marker combination comprises dehydroepiandrosterone sulfate, acylcarnitine 12: 0 and taurodeoxycholic acid. The plasma metabolism marker combination has high specificity, high sensitivity and non-invasiveness when being used for breast cancer detection, so that a subject can conveniently and safely receive detection, and the plasma metabolism marker combination is suitable for screening and detection of large-scale common people and is beneficial to early screening, early diagnosis and early treatment of breast cancer.
Owner:HARBIN METANOTITIA INC

Nutrional composition for treating and / or preventing muscle wasting

The invention pertains to a nutritional composition comprising taurine, carnitine and a mixture of low- molecular-weight polyphenols derived from lychee fruit and green tea leaves. Further, the invention pertains to a nutritional composition comprising taurine, carnitine and a mixture of low-molecular-weight polyphenols derived from lychee fruit and green tea leaves for use as a medicament, more particularly for therapeutic use in treating and / or preventing muscle wasting.
Owner:NV NUTRICIA

Injection composition for lipolysis

The present invention relates to an injection composition for lipolysis, which is safe and effective, and more specifically, to an injection composition for lipolysis, which comprises: one or more compounds selected from the group consisting of hyaluronidase and pentoxifylline, and one or more compounds selected from the group consisting of hyaluronidase, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline, pentoxifylline and pentoxifylline. 5 to 10% (v / v) of carnitine (Carnitine); and lidocaine (Lidocaine); and normal saline. As a composition having both safety and efficacy, the injection composition for lipolysis of the present invention has an excellent lipolysis effect, does not cause a yo-yo phenomenon over time, and thus has a characteristic of not causing side effects such as skin depression.
Owner:姜旼材

Chip, preparation method thereof and quantitative detection method of acyl carnitine

The invention provides a preparation method of a chip for quantitative detection of acyl carnitine in a high-coverage and high-sensitivity clinical sample. The preparation method comprises the following steps: A) preparing a silicon nanowire material; b) performing in-situ reduction modification on the gold nanoparticles by the silicon nanowire material to obtain an Au-SiNWs material; and C) carrying out a self-assembly reaction to prepare the Sulfo-Au-SiNWs material. According to the method, the ionization efficiency is enhanced through the synergistic effect of the introduced surface sulfonic acid groups and the gold nanoparticles, and the signal response of AC in a high-salt complex matrix is effectively improved. In the aspect of quantification, the innovatively designed full-spectrum internal standard method for perdeuterated ethanol derivatization avoids peak overlapping by utilizing isotope quality difference, breaks through the traditional quantification mode depending on a few standard substances, realizes high-coverage and high-accuracy quantitative analysis on AC in a clinical sample for the first time, and remarkably improves the universality and clinical operability of the method.
Owner:ZHEJIANG UNIV +2

Innovative formulation for cardiac support supplements using molecular-level mixing technology

The invention relates to an formulation for cardiac support supplements and the method of its preparation by using molecular-level mixing technology. The method involves preparing molecular-level emulsions of alpha-lipoic acid, acetyl L-carnitine, and coenzyme Q10, followed by spray drying to produce a homogeneous powder premix. This approach ensures precise dosage control, enhanced bioavailability, and improved stability, making it a valuable advancement in the field of nutraceutical and pharmaceutical formulations.
Owner:SADAANI MAHMOUD KHAFAGA ALI

Nutritional composition for alzheimer's disease population or high-risk population, and preparation method therefor

A nutritional composition for an Alzheimer's disease population or a high-risk population, prepared from the following raw materials in parts by weight: 170-300 parts of proteinaceous substances, 85-250 parts of fatty substances, 450-770 parts of carbohydrates, 10-155 parts of dietary fiber substances, 1.2-3.5 parts of trace minerals, 47-180 parts of macro minerals, 2.0-8.3 parts of vitamins, 0.1-1.0 parts of taurine, 0.05-0.5 parts of L-carnitine, and 0.9-1.0 parts of lactoferrin. The composition is rich in high-quality animal and plant proteins, fatty acids, various vitamins, minerals, and water-soluble dietary fibers, has remarkable effects in slowing down the occurrence and development of Alzheimer's disease, and is suitable for an Alzheimer's disease population or a high-risk population to eat.
Owner:HAINAN XINGZHENG NUTRITION ENGINEERING CO LTD

A combined biomarker for predicting intradialytic hypotension and a kit for detecting the same

The application discloses a combined biomarker for predicting hypotension in dialysis and a detection kit thereof, and the combined biomarker is 3-hydroxyisovaleryl carnitine, valine, phenylalanine and decadienoyl carnitine. The combined biomarker can better predict the risk of hypotension in dialysis of a subject in a discovery phase (AUC 0.804, sensitivity 77.5%) and an independent sample verification phase (AUC 0.804, sensitivity 90.0%). The detection method has the advantages of simple operation, few detection indexes, low cost, good specificity, high sensitivity, good repeatability and the like, and provides a simple and reliable method for early identification of a high-risk person of hypotension in dialysis and implementation of prevention intervention.
Owner:NINGBO MEDICAL CENT LIHUILI HOSPITACL